U.S. Bureau of Labor Statistics Nominee Tells Congress to “Flip the Script”: Denies Data Faking Claim, Emphasizes Agency Independence
BlockBeats News, June 11th, Brett Matsumoto, nominee for Commissioner of the U.S. Bureau of Labor Statistics, stated during a Senate confirmation hearing that no evidence of employment data manipulation or "falsification" had been found during his tenure, indirectly refuting previous controversies surrounding U.S. official statistics.
Earlier, former President Trump dismissed Bureau of Labor Statistics Commissioner Erika McEntarfer over a weak employment report and accused the related data of "artificial manipulation" without providing evidence, causing public concern.
During the hearing, Matsumoto stated that some significant data revisions may stem from technical factors and do not support allegations of "data falsification." He emphasized that if confirmed, he would be dedicated to upholding the professionalism and independence of the Bureau of Labor Statistics, ensuring that data is released on time and in compliance with the law.
At the same time, he pointed out that the agency is facing structural challenges such as funding constraints and declining survey response rates, which may affect the quality of future statistical data. He warned that the survey-based statistical system is facing long-term sustainability pressures and advocated for the introduction of additional data sources and technological tools (including business payroll data and artificial intelligence tools) to enhance statistical reliability.
The nomination is currently pending further review and confirmation by the Senate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
